K-80003

sulindac derivative that inhibits activation of phosphoinositide 3-kinase (PI3K) by retinoid X receptor alpha (RXRalpha) in tumor cells

Also Known As:

2-((3Z)-6-fluoro-2-methyl-3-((4-propan-2-ylphenyl)methylidene)inden-1-yl)acetic acid

Networked: 7 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Indenes: 4
        Sulindac: 994
        K-80003: 7
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Indenes: 4
    - Sulindac: 994
      - K-80003: 7

Experts

1.	Zhou, Hu: 4 articles (01/2019 - 06/2010)
2.	Su, Ying: 3 articles (01/2019 - 06/2010)
3.	Zhang, Xiao-Kun: 3 articles (01/2019 - 06/2010)
4.	He, Ben: 2 articles (12/2022 - 01/2019)
5.	Shen, Linghong: 2 articles (12/2022 - 01/2019)
6.	Sun, Zhe: 2 articles (12/2022 - 01/2019)
7.	Yuan, Ruosen: 2 articles (12/2022 - 01/2019)
8.	Wu, Hua: 2 articles (01/2019 - 06/2010)
9.	Ye, Xiaohong: 2 articles (01/2019 - 01/2017)
10.	Chen, Liqun: 2 articles (01/2018 - 01/2017)

Related Diseases

1.	Atherosclerotic Plaque (Atheroma) 01/01/2019 - "This study investigated whether and how an RXRα modulator, K-80003, derived from a non-steroidal anti-inflammatory drug attenuates atherosclerotic plaque progression and destabilization. " 01/01/2019 - "K-80003 suppressed atherosclerotic plaque progression and destabilization by promoting macrophage autophagic flux and consequently inhibited the p62/SQSTM1-mediated NF-κB proinflammatory pathway. " 12/01/2022 - "Nonsteroidal anti-inflammatory drug sulindac derivative K-80003 treatment was previously reported to dramatically attenuate atherosclerotic plaque progression and destabilization. "
2.	Neoplasms (Cancer) 01/01/2018 - "We also identified one analog, K-80003, which can inhibit cancer cell growth by inducing tRXRα to form a tetramer, thus disrupting p85α-tRXRα interaction. " 06/15/2010 - "K-80003 displayed enhanced efficacy in inhibiting tRXRalpha-dependent AKT activation and tRXRalpha tumor growth in animals." 01/01/2017 - "We previously discovered that an N-terminally-cleaved form of RXRα (tRXRα), produced in tumour cells, activates phosphoinositide 3-kinase (PI3K) signalling by binding to the p85α subunit of PI3K and that K-80003, an anti-cancer agent, inhibits this process. "
3.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2019 - "K-80003, a tRXRα modulator derived from nonsteroidal anti-inflammatory drug (NSAID) sulindac, suppresses the growth of tRXRα-mediated colorectal tumor by inhibiting the NF-κB-IL-6-STAT3 signaling cascade. "
4.	Rupture 01/01/2019 - "K-80003 significantly reduced lesion size, plaque rupture, macrophage infiltration, and inflammatory cytokine levels. "
5.	Pain (Aches) 01/01/2021 - "Retinoid X receptor α (RXRα) modulator K-80003 prevented the degeneration of articular cartilage, reduced synovial inflammation, and alleviated osteoarthritic pain in rats. "

Related Drugs and Biologics

1.	Sulindac (Copal)
2.	Retinoid X Receptors (Retinoid X Receptor)
3.	Cytokines
4.	Phosphatidylinositols (Phosphatidylinositol)
5.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)